Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.73 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 1/20 | 0.73 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13606789 | 1.00 | EGFR (0.77) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL4524312 | 1.00 | EGFR (0.77) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL13606791 | 1.00 | EGFR (0.77) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL4523013 | 1.00 | EGFR (0.77) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL1446388 | 0.95 | KDR (0.81) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL1446086 | 0.95 | KDR (0.81) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL1446083 | 0.95 | KDR (0.81) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL13606795 | 0.94 | EGFR (0.69) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL13606793 | 0.94 | EGFR (0.72) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL5906958 | 0.94 | FBP1 (0.73) | EGFRERBB2EPHA2KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306105-A1 | Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306105-A1 | Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306105-A1 | Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1996561-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM | Boehringer Ingelheim International GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007101782-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007101782-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306105-A1 | Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them | BPHL, CYP11B2, MAP3K1 | EGFR 508/4885ERBB2 161/4885EPHA2 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.